Ovid Therapeutics Net Worth
Ovid Therapeutics Net Worth Breakdown | OVID |
Ovid Therapeutics Net Worth Analysis
Ovid Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ovid Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ovid Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ovid Therapeutics' net worth analysis. One common approach is to calculate Ovid Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ovid Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ovid Therapeutics' net worth. This approach calculates the present value of Ovid Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ovid Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ovid Therapeutics' net worth. This involves comparing Ovid Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ovid Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Ovid Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ovid Therapeutics' net worth research are outlined below:
| Ovid Therapeutics generated a negative expected return over the last 90 days | |
| Ovid Therapeutics has some characteristics of a very speculative penny stock | |
| Ovid Therapeutics has high historical volatility and very poor performance | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 391.69 K. Net Loss for the year was (52.34 M) with profit before overhead, payroll, taxes, and interest of 1.5 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (45.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Biotechnology Value Fund L Ps Strategic Reduction in Ovid Therapeutics Inc |
Ovid Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ovid Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ovid Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ovid Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ovid Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ovid Therapeutics backward and forwards among themselves. Ovid Therapeutics' institutional investor refers to the entity that pools money to purchase Ovid Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosight Management, Lp | 2024-06-30 | 1.1 M | Tls Advisors Llc | 2024-09-30 | 771.5 K | Wells Fargo & Co | 2024-06-30 | 741.6 K | Ubs O'connor Llc | 2024-09-30 | 628.3 K | Northern Trust Corp | 2024-09-30 | 480.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 309.5 K | Gsa Capital Partners Llp | 2024-09-30 | 260.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 218.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 161.8 K | Rubric Capital Management Lp | 2024-06-30 | 5.3 M | Madison Avenue Partners, Lp | 2024-06-30 | 4.1 M |
Follow Ovid Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.11 M.Market Cap |
|
Project Ovid Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.60) | (0.63) |
When accessing Ovid Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ovid Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ovid Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Ovid Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.
Evaluate Ovid Therapeutics' management efficiency
Ovid Therapeutics has return on total asset (ROA) of (0.3604) % which means that it has lost $0.3604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3661) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Ovid Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.24 | 2.33 | |
| Tangible Book Value Per Share | 1.24 | 2.32 | |
| Enterprise Value Over EBITDA | (3.68) | (3.87) | |
| Price Book Value Ratio | 2.59 | 3.82 | |
| Enterprise Value Multiple | (3.68) | (3.87) | |
| Price Fair Value | 2.59 | 3.82 | |
| Enterprise Value | 216.2 M | 108.5 M |
The operational strategies employed by Ovid Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 48.2414 | Revenue 631.7 K | Quarterly Revenue Growth 0.587 | Revenue Per Share 0.009 | Return On Equity (0.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ovid Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ovid Therapeutics time-series forecasting models is one of many Ovid Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ovid Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ovid Therapeutics Earnings per Share Projection vs Actual
Ovid Therapeutics Corporate Management
| Meg Alexander | Chief Officer | Profile | |
| Claude MD | Head RD | Profile | |
| SPHR SHRMSCP | VP Facilities | Profile | |
| Jason MBA | Chief Officer | Profile | |
| Lora Pike | Senior Relations | Profile | |
| Garret Bonney | Investor Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.